[Etofibrate and clofibrate in a double-blind trial on patients with raised serum-lipid levels (author's transl)].
In a clinical trial of 21 patients with hypercholesteraemia and (or) hypertriglyceridaemia, the effects of etofibrate and clofibrate were compared with one another and against a placebo: both drugs lowered triglyceride levels significantly, but etofibrate also had a stronger cholesterol-lowering effect. Both substances were well tolerated.
D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000188:drug therapy*; D008433:Mathematics; D009539:Nicotinic Acids / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D014280:Triglycerides / Q000097:blood*
D009539:Nicotinic Acids; D010919:Placebos; D014280:Triglycerides; D002994:Clofibrate
Etofibrat und Clofibrat im Doppelblindversuch bei der Behandlung erhöhter Serumlipide